Opendata, web and dolomites

Vaprosep

Validation of Progranulin as Biomarker in Diagnostics and Prognosis of Sepsis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Vaprosep project word cloud

Explore the words cloud of the Vaprosep project. It provides you a very rough idea of what is the project "Vaprosep" about.

inducing    strategic    differentiation    opinion    prove    094    preliminary    hospital    economic    employees    patient    course    point    stay    picture    scientific    prognosis    reimbursement    interviewed    clinical    regulatory    notified    icu    property    progranulin    technically    length    leaders    therapy    excellent    contact    bodies    hospitals    care    host    500    health    market    subsequent    antibiotic    solidity    feasibility    disease    time    inflammatory    mean    incidence    biomarker    routine    qualified    worldwide    validated    completion    million    regarding    mediagnost    reduce    sepsis    sensitive    complete    day    direct    1000    successfully    infrastructure    infection    guarantee    12    unnecessary    questionnaire    agent    intellectual    monitoring    avoidance    administrative    infectious    detection    reaction    structured    literature    successful    delay    systemic    rate    multiplex    validation    data    advantages    therapeutic    strategy   

Project "Vaprosep" data sheet

The following table provides information about the project.

Coordinator
MEDIAGNOST GESELLSCHAFT FUR FORSCHUNG UND HERSTELLUNG VON DIAGNOSTIKA GMBH 

Organization address
address: ASPENHAUSTRASSE 25
city: REUTLINGEN
postcode: 72770
website: www.mediagnost.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.mediagnost.de/en/news/summary-of-sme-instrument-phase-i-project-vaprosep-2/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIAGNOST GESELLSCHAFT FUR FORSCHUNG UND HERSTELLUNG VON DIAGNOSTIKA GMBH DE (REUTLINGEN) coordinator 50˙000.00

Map

 Project objective

Sepsis is a complex, systemic and inflammatory host reaction on an infection and with worldwide 1.5 million cases per year a health challenge. There is a strong need for a reliable biomarker like progranulin. Preliminary data prove that progranulin allows a highly sensitive and specific detection of sepsis, a monitoring of infection without time delay, prognosis regarding disease course and a differentiation between the infectious agent inducing sepsis.

Economic advantages of progranulin as biomarker are the reduction of the length of stay in the ICU (500-1000€ / day) and avoidance of unnecessary antibiotic therapy (10-500€ / day). Thus, the hospital can improve patient care and reduce therapeutic costs by a progranulin measurement for 5-10€. A mean incidence rate of 0.094% results in a 12 million euro market in the US and EU. Based on intellectual property this market is available only for Mediagnost. Successfully validated, progranulin measurement will be introduced in third level hospitals in the EU. The subsequent strategic product development includes point of care and multiplex test systems.

Mediagnost already has a technically validated test system for this biomarker available, therefore the overall objectives of this study are the clinical validation of progranulin measurement in sepsis and its implementation in clinical routine. Specifically, in phase I the economic potential of this biomarker is evaluated.

These objectives are addressed during phase I in a feasibility study including market and cost analysis. Key opinion leaders in the EU are interviewed by a structured questionnaire to evaluate scientific solidity and market potential. In direct contact to EU Notified Bodies the best regulatory strategy is evaluated. Further, literature research will complete the picture of the market and reimbursement requirements. Excellent infrastructure and highly qualified scientific and administrative employees guarantee the successful completion of this work.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VAPROSEP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VAPROSEP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More